Carrie Bourdow
Chief Executive Officer chez TREVENA, INC.
Fortune : 43 442 $ au 31/03/2024
Profil
Carrie L.
Bourdow is currently the Chairman, President & Chief Executive Officer at Trevena, Inc. She previously served as an Independent Director at Sesen Bio, Inc. from 2020 to 2023 and at Nabriva Therapeutics Plc from 2017 to 2023.
Prior to that, she was the Vice President-Marketing at Cubist Pharmaceuticals LLC from 2013 to 2015.
Ms. Bourdow holds an undergraduate degree from Hendrix College and an MBA from Southern Illinois University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TREVENA, INC.
0,51% | 09/02/2024 | 93 214 ( 0,51% ) | 42 878 $ | 31/03/2024 |
NABRIVA THERAPEUTICS PLC
0,01% | 31/01/2023 | 397 ( 0,01% ) | 564 $ | 31/07/2023 |
Postes actifs de Carrie Bourdow
| Sociétés | Poste | Début |
|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 |
Anciens postes connus de Carrie Bourdow
| Sociétés | Poste | Fin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 30/07/2023 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07/03/2023 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2015 |
Formation de Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
